💨 Abstract

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil, and Mexico in 2025. The drug, already approved in China, could potentially benefit 900 million patients globally, as demand for diabetes and weight-loss drugs has been extraordinary for both Lilly and its Danish rival Novo Nordisk. The drug is currently sold under different brand names in different regions.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖